SLIT3
Overview
SLIT3 (Slit Guidance Ligand 3) is an extracellular matrix protein that acts as a repulsive guidance cue for axons and migrating cells through binding to Robo receptors. Its role in cancer is not well characterized; it has been identified as preferentially mutated in NSCLC tumors with durable clinical benefit from PD-1 blockade.
Alterations observed in the corpus
- Harbored deleterious mutations in ≥4 DCB patients and 0 NDB patients in a pembrolizumab NSCLC cohort; association not corrected for overall mutation burden and requires independent validation PMID:25765070
Cancer types (linked)
- NSCLC: Preferentially mutated in durable-clinical-benefit tumors on pembrolizumab PMID:25765070
Co-occurrence and mutual exclusivity
Therapeutic relevance
Open questions
- Association with pembrolizumab response is confounded by overall mutation burden elevation in DCB tumors and has not been independently validated PMID:25765070
Sources
This page was processed by crosslinker on 2026-05-14.